Market Overview

Loncar Cancer Immunotherapy Index Conducts Semi-Annual Rebalance

Share:





Loncar Investments, LLC today announced the result of the semi-annual
rebalance and reconstitution of the Loncar
Cancer Immunotherapy Index
, a group of the top 30 companies
developing cancer immunotherapy treatments and discovering new ways to
use the body's immune system to fight cancer.

The Committee has added Dynavax Technologies (NASDAQ:DVAX), Jounce
Therapeutics (NASDAQ:JNCE) and Syndax Pharmaceuticals (NASDAQ:SNDX) to
the index.

These additions replace Compugen (NASDAQ:CGEN), NewLink Genetics
(NASDAQ:NLNK) and Sorrento Therapeutics (NASDAQ:SRNE).

"The immunotherapy field is just now gathering momentum and we are
optimistic the best is yet to come. The number of FDA approvals for the
types of immunotherapy drugs tracked by the index has doubled since May
of last year," said Brad Loncar, Chairman of the index committee.
"Innovative companies like the three we have added today are working on
the next wave of immunotherapy treatments that we hope will result in
even better outcomes for more patients."

Effective this week, all index holdings have been rebalanced to hold
equal weight. The index is rebalanced and reconstituted semi-annually.
The next rebalance will occur on December 19, 2017.

Loncar Investments is an official partner of the Cancer
Research Institute
, the world's only nonprofit organization
dedicated exclusively to harnessing the immune system's power to conquer
all cancers. June is Cancer Immunotherapy Month and we are especially
thankful at this time of year for CRI's distinguished record of
supporting immunotherapy. To learn about how to give to CRI, please
visit here.

Why immunotherapy: Cancer immunotherapy has become an important
sector in the biotechnology space and is changing the way many cancers
are treated. While traditional medicines like chemotherapies often give
cancer a broad punch, the benefit of using immunotherapy is derived from
the immune system's dynamic nature and the way it can more precisely be
tailored to fight a patient's disease. Some immunotherapies have already
exhibited uncommon results in clinical trials including partial and
complete responses in late stage cancer patients.

About the index: The Loncar Cancer Immunotherapy Index is an
equal-weighted index of 30 top immunotherapy companies rebalanced and
reconstituted on a semi-annual basis. Price and return data are
independently calculated on a daily basis by Indxx, LLC. This is a
sector index similar to Technology sector indices (Internet, Cyber
Security, Cloud Computing, etc.). Sector indices allow investors to
track interest areas more precisely than broad indices. Additional
information can be found at the index's dedicated website, www.LoncarIndex.com.

Index provider: Loncar Investments, LLC is committed to making
the biotechnology space more approachable to a wider range of investors.
The company is principally owned by biotech investor and analyst Brad
Loncar. Mr. Loncar manages a biotech-focused family portfolio from his
Lenexa, Kan. office. He can be followed on Twitter at @bradloncar
and his commentary is available at www.loncarblog.com.

View Comments and Join the Discussion!
 
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com